Effects of TMEM232 Variant on Infant Atopic Dermatitis According to Maternal Factors

Genes (Basel). 2024 Nov 8;15(11):1446. doi: 10.3390/genes15111446.

Abstract

Background: Atopic dermatitis (AD) is caused by interactions between genetic susceptibility and environmental factors. Transmembrane protein 232 (TMEM232) is one of the genes strongly implicated in AD. Methods: In the present study, we aimed to investigate the association between AD with variants within TMEM232 based on maternal factors, including a history of allergic diseases, and sensitization to Der f. We performed a candidate gene association study involving the Cohort for Childhood Origins of Asthma and Allergic Diseases. Results: A single variant of the TMEM232 gene, rs17132261, was found to be significantly associated with AD. Subjects carrying the wild-type allele (C) of rs17132261 had higher total IgE than those carrying the variant rs17132261 (T). Multiple logistic regression analysis showed a statistically significant association between TMEM232 gene polymorphism and an increased risk of AD in one-year-old infants. Moreover, rs17132261 was associated with increased total IgE in infants with a maternal history of allergic disease. The group with the CC genotype showed a higher risk of developing AD compared to carriers of CT and TT genotypes when the mother had a history of allergic diseases or was sensitized to Der f. Conclusions: Our findings demonstrate that the TMEM232 risk allele, in combination with maternal factors, higher the total IgE, which could be a potential risk factor for AD.

Keywords: TMEM232; atopic dermatitis; maternal factor; total IgE.

MeSH terms

  • Adult
  • Alleles
  • Dermatitis, Atopic* / genetics
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Immunoglobulin E* / blood
  • Infant
  • Male
  • Membrane Proteins* / genetics
  • Polymorphism, Single Nucleotide*
  • Risk Factors

Substances

  • Membrane Proteins
  • Immunoglobulin E

Grants and funding

This study was supported by the Korea National Institute of Health (2020-NG-007-00, 2020-NG-007-01, 2020-NG-007-02, 2023-NI-008-00, 2017-E67002-00, 2017-E67002-01, 2017-E67002-02, 2020-E6702-00, and 2020-E6702-01).